Trial · NCT03519984
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
NCT03519984, Phase 1, Terminated, University of Southern California
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia. Trials, record NCT03519984. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03519984
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
- NCT number
- NCT03519984
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Southern California
- Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein, Vincristine Liposomal
- First posted
- 2018-05-09
- Last updated
- 2021-11-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse events | Up to 24 months | Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and summarized for each course separately. |
| Primary | Best clinical response in the blood and bone marrow observed at anytime during single agent treatment with recombinant EphB4-HSA fusion protein alone | Up to 24 months | Best clinical response defined as complete remission (CR) + complete remission with incomplete blood count recovery (CRi) + partial remission (PR) + partial remission with incomplete blood count recovery (PRi). CR defined as Neutrophils: \>1,000/µL; Platelets: \>100,000/µL; Bone Marrow Blasts: \<5% with spicules, no Auer rods; Other: Transfusion independent, no extra medullary disease. CRi defined as Neutrophils: \<1,000/µL; Platelets: \<100,000/µL; Bone Marrow Blasts: \<5%; Other: Either neutrophils or platelets not recovered, no extra medullary disease. PR defined as Neutrophils: \>1,000/µL; Platelets: \>100,000/µL; Bone Marrow Blasts: decrease to 5-25 and = \> 50% decrease from start. PRi defined as Neutrophils: \<1,000/µL; Platelets: \<100,000/µL; Bone Marrow Blasts: decrease to 5-25 and = \> 50% decrease from start. |
| Primary | Complete remission (CR) and complete remission with incomplete blood count recovery (CRi) observed at anytime for the combination with cytarabine or liposomal vincristine | Up to 24 months | CR defined as Neutrophils: \>1,000/µL; Platelets: \>100,000/µL; Bone Marrow Blasts: \<5% with spicules, no Auer rods; Other: Transfusion independent, no extra medullary disease. CRi defined as Neutrophils: \<1,000/µL; Platelets: \<100,000/µL; Bone Marrow Blasts: \<5%; Other: Either neutrophils or platelets not recovered, no extra medullary disease. |
| Secondary | Progression-free survival (PFS) | Up to 24 months | Will be calculated for all patients who achieve a CR or CRi from first documentation ofCR or CRi to recurrence or death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | LERMAN, CARYN | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03519984
GET https://conductscience.org/api/trials/v1/NCT03519984/registered